NZ335108A - Methods of inhibiting stem cell proliferation by contacting hematopoietic cells with an inhibiting amount of INPROL - Google Patents

Methods of inhibiting stem cell proliferation by contacting hematopoietic cells with an inhibiting amount of INPROL

Info

Publication number
NZ335108A
NZ335108A NZ335108A NZ33510895A NZ335108A NZ 335108 A NZ335108 A NZ 335108A NZ 335108 A NZ335108 A NZ 335108A NZ 33510895 A NZ33510895 A NZ 33510895A NZ 335108 A NZ335108 A NZ 335108A
Authority
NZ
New Zealand
Prior art keywords
inhibiting
inprol
stem cell
cell proliferation
hemoglobin
Prior art date
Application number
NZ335108A
Other languages
English (en)
Inventor
Vladimir Kozlov
Irena Tsyrlova
Stephen D Wolpe
Original Assignee
Pro Neuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/316,424 external-priority patent/US6022848A/en
Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc
Publication of NZ335108A publication Critical patent/NZ335108A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M11/00—Telephonic communication systems specially adapted for combination with other electrical systems
    • H04M11/002—Telephonic communication systems specially adapted for combination with other electrical systems with telemetering systems
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04M—TELEPHONIC COMMUNICATION
    • H04M11/00—Telephonic communication systems specially adapted for combination with other electrical systems
    • H04M11/04—Telephonic communication systems specially adapted for combination with other electrical systems with alarm systems, e.g. fire, police or burglar alarm systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Signal Processing (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Endocrinology (AREA)
NZ335108A 1994-09-30 1995-09-29 Methods of inhibiting stem cell proliferation by contacting hematopoietic cells with an inhibiting amount of INPROL NZ335108A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/316,424 US6022848A (en) 1993-03-31 1994-09-30 Inhibitor of stem cell proliferation and uses thereof
US08/535,882 US5939391A (en) 1993-03-31 1995-09-28 Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation

Publications (1)

Publication Number Publication Date
NZ335108A true NZ335108A (en) 2000-11-24

Family

ID=26980434

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ335108A NZ335108A (en) 1994-09-30 1995-09-29 Methods of inhibiting stem cell proliferation by contacting hematopoietic cells with an inhibiting amount of INPROL
NZ294446A NZ294446A (en) 1994-09-30 1995-09-29 Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ294446A NZ294446A (en) 1994-09-30 1995-09-29 Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.

Country Status (17)

Country Link
US (2) US5939391A (enExample)
EP (1) EP0784677B1 (enExample)
JP (3) JP3953511B2 (enExample)
CN (2) CN1328285C (enExample)
AT (1) ATE263236T1 (enExample)
CA (1) CA2201105C (enExample)
DE (1) DE69532813T2 (enExample)
DK (1) DK0784677T3 (enExample)
ES (1) ES2216019T3 (enExample)
FI (1) FI117468B (enExample)
IL (1) IL115473A (enExample)
MX (1) MX9702266A (enExample)
NO (1) NO319575B1 (enExample)
NZ (2) NZ335108A (enExample)
PT (1) PT784677E (enExample)
RU (1) RU2186579C2 (enExample)
WO (1) WO1996010634A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU712204C (en) * 1993-03-31 2004-02-26 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
US5939391A (en) * 1993-03-31 1999-08-17 Pro-Neuron, Inc. Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
RU2155066C2 (ru) 1993-03-31 2000-08-27 Про-Ньюрон, Инк. Ингибитор пролиферации стволовых клеток и его использование
US6610654B2 (en) * 1993-03-31 2003-08-26 Wellstat Therapeutics Corporation Inhibitor of stem cell proliferation and uses thereof
US5861483A (en) 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof
GB9700154D0 (en) * 1997-01-07 1997-02-26 Primapharma Ltd Peptides
JP2000095794A (ja) * 1998-09-22 2000-04-04 Itoham Foods Inc エンケファリン分解酵素の阻害剤
US6488828B1 (en) * 2000-07-20 2002-12-03 Roche Diagnostics Corporation Recloseable biosensor
WO2005026380A2 (en) * 2003-09-10 2005-03-24 Southern Research Institute Bone marrow proliferation assay
NZ591827A (en) 2005-07-26 2012-10-26 Cms Peptides Patent Holding Company Ltd Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
RU2317074C1 (ru) * 2006-03-16 2008-02-20 Общество с ограниченной ответственностью "МБФ" Ингибитор дифференцировки кроветворных клеток-предшественников
RU2320364C1 (ru) * 2006-08-21 2008-03-27 Закрытое Акционерное Общество "Центр "Пептос" Способ лечения злокачественных новообразований
RU2328304C1 (ru) * 2007-03-22 2008-07-10 Общество с ограниченной ответственностью "Геленпол" Агент защиты клеток крови и восстановления кроветворной системы и фармакологическая комбинация для лечения онкологических больных
WO2008136699A1 (fr) * 2007-05-04 2008-11-13 Igor Alexandrovich Bazikov Patch transdermique à microcapsules et procédé de fabrication correspondant
US9782452B2 (en) * 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
US9220706B2 (en) 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
WO2014078787A1 (en) * 2012-11-19 2014-05-22 Wellstat Therapeutics Corporation Stem cell mobilization and tissue repair and regeneration
RU2535972C2 (ru) * 2012-12-24 2014-12-20 Андрей Степанович БРЮХОВЕЦКИЙ Противоопухолевый индивидуальный протеом-основанный таргетный клеточный препарат, способ его получения и применение этого препарата для терапии рака и других злокачественных новообразований
RU2537141C1 (ru) * 2013-11-20 2014-12-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ определения способности клеток костного мозга к делению
CN104817625A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd03及其制备方法和应用
CN104817613A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd06及其制备方法和应用
CN104817615A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd05及其制备方法和应用
CN104817622A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd04及其制备方法和应用
CN105294830A (zh) * 2014-06-18 2016-02-03 陈光健 一种二肽分子及其制备方法和应用
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1142466A (en) * 1979-01-09 1983-03-08 National Research Development Corporation Cell lines
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
NZ233642A (en) * 1989-05-10 1992-12-23 Somatogenetics Int Linked hemoglobin subunits, preparation by genetic engineering and linker assay
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
DE69020573T3 (de) * 1989-09-25 1999-12-16 Crc Technology Ltd., London Verfahren zur wachstumshemmung von stammzellen.
US5239061A (en) * 1990-06-20 1993-08-24 Research Corporation Technologies, Inc. Modified human hemoglobin, blood substitutes containing the same, and vectors for expressing the modified hemoglobin
AU668856B2 (en) * 1990-12-20 1996-05-23 University Of Alabama Research Foundation, The Transgenic, cross-linked hemoglobin
WO1992020369A1 (en) * 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5334706A (en) * 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
US5786334A (en) * 1992-08-14 1998-07-28 Technology Resources International, Inc. Hexapeptide having immunostimulatory activity
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5939391A (en) * 1993-03-31 1999-08-17 Pro-Neuron, Inc. Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation
US5861483A (en) * 1996-04-03 1999-01-19 Pro-Neuron, Inc. Inhibitor of stem cell proliferation and uses thereof

Also Published As

Publication number Publication date
CN1321688C (zh) 2007-06-20
FI971000L (fi) 1997-05-28
NZ294446A (en) 1999-07-29
ATE263236T1 (de) 2004-04-15
MX9702266A (es) 1997-06-28
EP0784677A4 (en) 2002-01-30
EP0784677B1 (en) 2004-03-31
CN1168695A (zh) 1997-12-24
US5939391A (en) 1999-08-17
JPH10509422A (ja) 1998-09-14
NO971444D0 (no) 1997-03-26
CN1328285C (zh) 2007-07-25
CA2201105C (en) 2009-11-24
HK1108701A1 (zh) 2008-05-16
HK1071517A1 (en) 2005-07-22
DK0784677T3 (da) 2004-08-02
WO1996010634A1 (en) 1996-04-11
EP0784677A1 (en) 1997-07-23
IL115473A (en) 2005-08-31
CN1565627A (zh) 2005-01-19
HK1006642A1 (zh) 1999-03-12
JP4188279B2 (ja) 2008-11-26
PT784677E (pt) 2004-08-31
RU2186579C2 (ru) 2002-08-10
IL115473A0 (en) 1995-12-31
FI971000A0 (fi) 1997-03-11
FI117468B (fi) 2006-10-31
US6090782A (en) 2000-07-18
NO971444L (no) 1997-05-26
CA2201105A1 (en) 1996-04-11
JP2004256553A (ja) 2004-09-16
JP3953511B2 (ja) 2007-08-08
DE69532813D1 (de) 2004-05-06
NO319575B1 (no) 2005-08-29
DE69532813T2 (de) 2005-03-17
ES2216019T3 (es) 2004-10-16
JP2008088186A (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
IL110754A0 (en) Cell compositions preparation and therapeutic uses
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
AU580076B2 (en) Dental preparation, article and method for storage and delivery thereof
IL81168A0 (en) Haloarylnitrile degrading gene,its use,and cells containing the same
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
ZA899725B (en) N-aryl-azetidinones,their preparation process and their use as elastage inhibitors
EP0316738A3 (en) Process for the preparation of polyisocyanates containing methane groups, and their use
GR3035413T3 (en) Method of treating cell damage or depletion.
EP0722328A4 (en) INCREASING THE NUMBER OF HEMATOPOIETIC PROCUREMENT CELLS IN PERIPHERAL BLOOD BY MEANS OF THE TRANSFORMING GROWTH FACTOR BETA
AU6974294A (en) Release and mobilisation of haematopoietic cells
NZ294446A (en) Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
NO941327D0 (no) TCMTB på en bærer i pulverform, fremgangsmåte for fremstilling og fremgangsmåte for anvendelse
AU6642994A (en) Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
AU5897796A (en) Dna sequences encoding a lycopene cyclase, antisense sequenc es derived therefrom and their use for the modification of c arotenoids levels in plants
EP0656069A4 (en) CELL PROLIFERATION INHIBITORS, THEIR PRODUCTION AND USE.
ATE216425T1 (de) Verwendung von interferon-gamma zur vermeidung der proliferation und differenzierung der primitiven hämapoietischen vorläuferzellen
CA2227241A1 (en) Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
AU7226391A (en) Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess
NZ322227A (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
CA2151123A1 (fr) Cellules modifiees au niveau du catabolisme de la betaine, preparation et utilisations, notamment pour la production de metabolites ou d'enzymes
EP0358536A3 (en) Novel s-adenosyl methionine decarboxylase inhibitors
AU5105385A (en) Hydraulic cement composition incorporating calcium nitrite, thiocyanate(s) and optionally amino alcohol(s)
AU4299696A (en) Use of the hepatocyte growth factor to induce proliferation and differentiation of hemopoietic cells

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
S38A Application for proceedings under section 38 (amendment of specification with leave of commissioner)

Free format text: TO CORRECT CLERICAL ERRORS

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)